
Glibenclamide And Metformin Oral Tablets (Immediate-Release) Suppliers & Bulk Manufacturers
Available Forms: Tablets IR
Available Strengths: Glibenclamide 2.5 mg + Metformin 500 mg; Glibenclamide 5 mg + Metformin 500 mg
Reference Brands: Glucovance®,®, Euglucon-M®, Glyburid-M®(EU & US)
Category: Diabetes
Glibenclamide and Metformin Oral Tablets (Immediate-Release) is available in Tablets IR and strengths such as Glibenclamide 2.5 mg + Metformin 500 mg; Glibenclamide 5 mg + Metformin 500 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Glibenclamide and Metformin Oral Tablets (Immediate-Release) is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
Technical Specifications & Supply Details | |
---|---|
Lead Time | 7 to 60 days (depending on batch size & schedule) |
MOQ | As per manufacturer’s batch size |
COA | Available with every batch |
Regulatory Dossier / DMF | Available upon request |
Export Documentation | FSC, COA, Manufacturing License, Product Permission |
Standards | IP, BP, USP |
Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Glibenclamide and Metformin Oral Tablets (Immediate-Release) can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description: Glibenclamide (Glyburide) + Metformin tablets are approved in several EU countries under fixed-dose combinations and were previously marketed in the USA as Glucovance®. However, due to evolving safety guidelines—especially related to hypoglycemia risk—its availability may vary. In the EU, these combinations are still prescribed under close monitoring for type 2 diabetes management. The European Medicines Agency (EMA) requires risk-benefit evaluation and labeling for renal monitoring. The U.S. FDA formerly approved Glucovance® under NDA 021178. Healthcare buyers and distributors can find these formulations via Pharmatradz.com for compliant global sourcing.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Related Products
Alogliptin+Pioglitazone
Strength:
12.5 mg / 30 mg, 25 mg / 15 mg, 25 mg / 30 mg, 25 mg / 45 mg
Form: Tablets
Reference Brands: Oseni (USA), Incresync(EU)
View DetailsAlogliptin+Metformin
Strength:
12.5mg+500mg / 12.5mg+850mg / 12.5mg+1000mg
Form: Tablets
Reference Brands: Kazano (USA), Vipdomet (EU)
View DetailsNph Human Insulin (Rdna Origin)
Strength:
40U/ml, 100U/ml
Form: Injection
Reference Brands: Humulin (USA), Novolin (USA), Actrapid (EU/UK)
View DetailsAlogliptin
Strength:
6.25 mg, 12.5 mg, 25 mg
Form: Tablet
Reference Brands: Nesina (USA/EU), Kazano (USA), Vipidia (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers